Cardiovascular Drugs Practice Questions

Q: Alprostadil is not used for the treatment of which of the following conditions?

Patent ductus arteriosus. **Explanation:** The correct answer is **C. Patent ductus arteriosus**. This question requires a careful distinction between **maintaining** a ductus and **treating** a patent one. Alprostadil is a synthetic analogue of **Prostaglandin E1 (PGE1)**. Its primary physiological effect is potent vasodilation and relaxation of smooth muscles. 1. **Why Option C is correct:** In neonates with ductal-dependent congenital heart defects (e.g., Transposition of Great Arteries), Alprostadil is used to **keep the ductus arteriosus open** (maintain patency) to allow for life-saving oxygenation. It does **not** treat a Patent Ductus Arteriosus (PDA); rather, it prevents its closure. To *treat* or close a PDA, prostaglandin synthesis inhibitors like **Indomethacin or Ibuprofen** are used. 2. **Why other options are incorrect:** * **Erectile Dysfunction (A):** Alprostadil (administered via intracavernosal injection or urethral suppository) relaxes the smooth muscle of the corpus cavernosum, increasing blood flow. * **Pulmonary Hypertension (B):** Due to its potent vasodilatory properties, it can be used to reduce pulmonary vascular resistance, though it is less common than Epoprostenol. * **Critical Limb Ischemia (D):** It is used to improve limb perfusion and promote ulcer healing in patients with severe peripheral arterial disease who are not candidates for surgery. **High-Yield Clinical Pearls for NEET-PG:** * **PGE1 (Alprostadil):** "P" for **P**umping blood (keeps ductus open) and **P**enis (erection). * **PGE2 (Dinoprostone):** Used for cervical ripening and induction of labor. * **PGF2α (Carboprost):** Used for Postpartum Hemorrhage (PPH) but contraindicated in asthma. * **PGI2 (Epoprostenol):** Primary prostaglandin used for Pulmonary Hypertension.

Q: Niacin must be used cautiously in diabetic patients because?

It impairs insulin sensitivity. **Explanation:** **Niacin (Nicotinic Acid)** is a potent lipid-lowering agent that inhibits the mobilization of free fatty acids from peripheral adipose tissue. However, its use in diabetic patients is limited due to its metabolic side effects. **Why the correct answer is right:** Niacin induces **insulin resistance** (impairs insulin sensitivity). The primary mechanism involves the inhibition of glucose utilization in peripheral tissues and an increase in hepatic gluconeogenesis. This leads to a rise in fasting blood glucose levels, a phenomenon often referred to as **"Niacin-induced hyperglycemia."** While it is not an absolute contraindication, it requires cautious monitoring and potential adjustment of antidiabetic medications. **Why the other options are wrong:** * **Option A:** Niacin causes **hyperglycemia**, not hypoglycemia, due to decreased insulin sensitivity. * **Option C:** Niacin does not significantly induce or inhibit the cytochrome P450 enzymes responsible for the metabolism of most oral hypoglycemic agents. The interaction is pharmacodynamic (opposing effects on blood sugar), not pharmacokinetic. * **Option D:** Niacin does not increase skin thickness. Its most common cutaneous side effect is **cutaneous flushing** and pruritus, mediated by Prostaglandin $D_2$ and $E_2$. **NEET-PG High-Yield Pearls:** * **Side Effect Management:** Niacin-induced flushing can be blunted by pre-treatment with **Aspirin** (NSAIDs) 30 minutes prior. * **Lipid Profile:** Niacin is the most effective drug for **increasing HDL** levels. * **Other Side Effects:** It can cause **hyperuricemia** (precipitating gout) and is potentially hepatotoxic. * **Contraindications:** Active peptic ulcer disease, gout, and chronic liver disease.

Q: Which drug class inhibits the rate-limiting step in cholesterol synthesis?

Statins. **Explanation:** **Statins (HMG-CoA Reductase Inhibitors)** are the correct answer because they competitively inhibit the enzyme **HMG-CoA reductase**. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is the **rate-limiting step** in the endogenous synthesis of cholesterol in the liver. By reducing intracellular cholesterol levels, statins trigger an up-regulation of LDL receptors, leading to increased clearance of LDL from the plasma. **Analysis of Incorrect Options:** * **Probucol (A):** An older antioxidant drug that lowers LDL by increasing its catabolism and inhibits the oxidation of LDL. It is rarely used today due to its potential to lower HDL and prolong the QT interval. * **Cholestyramine (C):** A **Bile Acid Sequestrant**. It works in the intestine by binding to bile acids, preventing their enterohepatic circulation. This forces the liver to use more cholesterol to synthesize new bile acids, indirectly lowering plasma cholesterol. * **Gemfibrozil (D):** A **Fibrate**. Its primary mechanism is the activation of **PPAR-α** (Peroxisome Proliferator-Activated Receptor-alpha), which increases the activity of lipoprotein lipase. It is primarily used to lower triglycerides rather than cholesterol. **High-Yield Clinical Pearls for NEET-PG:** * **Pleiotropic Effects:** Statins have benefits beyond lipid-lowering, including plaque stabilization, anti-inflammatory effects, and improved endothelial function. * **Adverse Effects:** The most significant side effects are **myopathy/rhabdomyolysis** (monitored via CK levels) and **hepatotoxicity** (monitored via LFTs). * **Timing:** Statins with short half-lives (e.g., Simvastatin, Lovastatin) should be taken at **bedtime** because peak cholesterol synthesis occurs during the night. * **Contraindication:** Statins are strictly **contraindicated in pregnancy** (Teratogenic).

Q: Nitrate causes all of the following EXCEPT:

Increase in cardiac work. **Explanation:** Nitrates are primarily **venodilators** that act by releasing Nitric Oxide (NO), which increases cGMP levels, leading to smooth muscle relaxation. **Why "Increase in cardiac work" is the correct answer:** Nitrates **decrease** cardiac work, not increase it. By causing significant peripheral venodilation, they increase venous capacitance and decrease venous return to the heart (preload). This reduction in preload leads to a decrease in ventricular wall tension and myocardial oxygen demand. Consequently, the total workload of the heart is reduced, which is the primary mechanism for relieving angina. **Analysis of other options:** * **Decrease in heart size:** By reducing preload and ventricular end-diastolic volume (EDV), the physical dimensions of the heart (stretch) decrease. * **Preload reduction:** This is the hallmark pharmacological effect of nitrates. They increase venous pooling, thereby reducing the volume of blood returning to the right atrium. * **Dilatation of cutaneous blood vessels:** Nitrates cause vasodilation of superficial vessels, particularly in the "blush area" (face and neck), which clinically manifests as flushing. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Sublingual Nitroglycerin is the DOC for acute anginal attacks due to its rapid onset and avoidance of first-pass metabolism. * **Nitrate Tolerance:** Continuous exposure leads to "tachyphylaxis." A "nitrate-free interval" of 8–12 hours (usually at night) is required to restore sensitivity. * **Monday Disease:** Workers in explosives factories develop tolerance during the week but lose it over the weekend, leading to severe headaches and tachycardia upon re-exposure on Mondays. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can cause life-threatening hypotension.

Q: Riociguat is used in the treatment of:

Chronic thromboembolic pulmonary hypertension. **Explanation:** **Riociguat** is a first-in-class **soluble Guanylate Cyclase (sGC) stimulator**. Its primary mechanism of action involves sensitizing sGC to endogenous Nitric Oxide (NO) and directly stimulating the enzyme independently of NO. This leads to increased synthesis of cyclic Guanylate Monophosphate (cGMP), resulting in potent vasodilation, anti-proliferative, and anti-fibrotic effects on the pulmonary vasculature. **Why Option C is correct:** Riociguat is FDA-approved for two specific indications: 1. **Chronic Thromboembolic Pulmonary Hypertension (CTEPH):** Specifically in patients who have persistent/recurrent pulmonary hypertension after surgical endarterectomy or those with inoperable CTEPH. 2. **Pulmonary Arterial Hypertension (PAH):** To improve exercise capacity (WHO Group 1). **Why other options are incorrect:** * **Options A & B (Gouty/Rheumatoid Arthritis):** These are inflammatory joint disorders. Riociguat has no anti-inflammatory or uricosuric properties. Drugs like NSAIDs, Colchicine, or DMARDs are used here. * **Option D (Obesity):** Riociguat does not affect metabolic rate or appetite. Drugs like Orlistat or GLP-1 agonists (Liraglutide) are indicated for obesity. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindication:** It must **never** be co-administered with **PDE-5 inhibitors** (e.g., Sildenafil) or **Nitrates** due to the risk of severe, life-threatening hypotension. * **Teratogenicity:** It is contraindicated in pregnancy (Category X) and requires a restricted distribution program (REMS) in many regions. * **Side Effects:** Headache, dizziness, and dyspepsia are the most common adverse effects.

Q: A diabetic patient with bilateral renal artery stenosis requires a drug for the treatment of high blood pressure. Which of the following drugs will be most appropriate for this patient?

Amlodipine. **Explanation:** The correct answer is **D. Amlodipine.** **Why Amlodipine is the correct choice:** In patients with **bilateral renal artery stenosis (RAS)**, the glomerular filtration rate (GFR) is maintained by Angiotensin II-mediated vasoconstriction of the efferent arteriole. Amlodipine, a **Dihydropyridine Calcium Channel Blocker (CCB)**, acts by causing peripheral vasodilation without interfering with the renin-angiotensin-aldosterone system (RAAS). It effectively lowers blood pressure without compromising renal perfusion or GFR in the setting of RAS. Furthermore, CCBs are metabolically neutral, making them safe for diabetic patients. **Why other options are incorrect:** * **Enalapril (ACE Inhibitor):** This is **strictly contraindicated** in bilateral RAS. ACE inhibitors block the production of Angiotensin II, leading to vasodilation of the efferent arteriole. This causes a precipitous drop in intraglomerular pressure, resulting in acute renal failure. * **Hydrochlorothiazide (Thiazide Diuretic):** While not contraindicated in RAS, diuretics can worsen hyperglycemia and dyslipidemia, making them less ideal as first-line agents for diabetic patients. * **Metoprolol (Beta-blocker):** Beta-blockers can mask the symptoms of hypoglycemia (except sweating) and may impair the metabolic recovery from hypoglycemic episodes in diabetic patients. They are generally not the first-line choice for uncomplicated hypertension. **High-Yield Clinical Pearls for NEET-PG:** * **ACEIs/ARBs** are the drugs of choice for diabetics with proteinuria but are **absolute contraindications** in bilateral renal artery stenosis (or stenosis in a solitary kidney). * If a patient’s serum creatinine rises by **>30%** after starting an ACE inhibitor, suspect underlying Renal Artery Stenosis. * **Amlodipine** is preferred in RAS because it dilates the *afferent* arteriole more than the efferent, helping maintain GFR.

Q: Propranolol can be used in all of the following conditions except?

Variant angina. **Explanation:** The correct answer is **Variant angina (Prinzmetal angina)**. Propranolol is a non-selective beta-blocker that is strictly contraindicated in this condition. **1. Why Variant Angina is the correct answer:** Variant angina is caused by **coronary artery vasospasm** rather than atherosclerosis. In the coronary vessels, there are both $\beta_2$ receptors (which cause vasodilation) and $\alpha_1$ receptors (which cause vasoconstriction). Propranolol blocks the $\beta_2$ receptors, leaving the $\alpha_1$-mediated vasoconstrictive effects **unopposed**. This can worsen the coronary spasm, potentially leading to myocardial infarction. **2. Analysis of Incorrect Options:** * **Thyrotoxicosis:** Propranolol is the drug of choice to control symptomatic tachycardia, tremors, and palpitations. It also uniquely inhibits the peripheral conversion of $T_4$ to the more active $T_3$. * **Migraine:** Propranolol is a first-line agent for the **prophylaxis** of migraine (not for acute attacks) due to its high lipid solubility and ability to cross the blood-brain barrier. * **Hypertension:** While no longer first-line for uncomplicated hypertension, beta-blockers remain an option, especially in patients with co-existing conditions like stable angina or post-MI. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for Variant Angina:** Calcium Channel Blockers (CCBs) like Diltiazem or Nitrates. * **Other Contraindications for Propranolol:** Bronchial asthma/COPD (due to $\beta_2$ blockade causing bronchospasm), Bradycardia, and Second/Third-degree Heart Block. * **Metabolic effect:** Propranolol can mask the warning symptoms of hypoglycemia (tachycardia) in diabetic patients, except for sweating (which is mediated by cholinergic receptors).

Q: Which of the following is a potassium channel opener?

Nicorandil. **Explanation:** **Correct Answer: A. Nicorandil** Nicorandil is a unique anti-anginal drug with a dual mechanism of action. It acts as a **Potassium Channel Opener ($K_{ATP}$ channels)** and a **Nitric Oxide (NO) donor**. By opening ATP-sensitive $K^+$ channels in vascular smooth muscle, it causes potassium efflux, leading to hyperpolarization and subsequent closure of voltage-gated calcium channels. This results in significant **arteriolar dilation** (reducing afterload). Simultaneously, its nitrate moiety increases cGMP, causing **venous dilation** (reducing preload). This dual action effectively reduces myocardial oxygen demand and improves coronary blood flow. **Analysis of Incorrect Options:** * **B. Ranolazine:** This is a **late sodium channel blocker**. It prevents the overload of intracellular calcium via the $Na^+/Ca^{2+}$ exchanger, thereby improving myocardial relaxation and reducing wall tension without affecting heart rate or blood pressure. * **C. Ivabradine:** This drug is a selective **$I_f$ (funny) current inhibitor** in the SA node. It reduces heart rate without affecting myocardial contractility or conduction, making it a "pure" bradycardic agent. * **D. Nitroprusside:** This is a potent **vasodilator** that acts by releasing Nitric Oxide (NO). It does not act on potassium channels; it stimulates guanylyl cyclase to increase cGMP, causing both arterial and venous dilation. **High-Yield Clinical Pearls for NEET-PG:** * **Nicorandil Side Effect:** A characteristic and high-yield side effect is **persistent mucosal ulceration** (oral, anal, or perianal ulcers). * **Preconditioning:** Nicorandil mimics "ischemic preconditioning," providing a cardioprotective effect during MI. * **Other K+ Channel Openers:** Minoxidil, Diazoxide (used in hypertensive emergencies/insulinoma), and Pinacidil.

Question 1

Alprostadil is not used for the treatment of which of the following conditions?

Accepted Answer

Patent ductus arteriosus

Answer

Erectile dysfunction

Answer

Pulmonary hypertension

Answer

Critical limb ischemia

Question 2

Which antiarrhythmic drug can be used for arrhythmias refractory to lignocaine treatment?

Accepted Answer

Amiodarone

Answer

Sotalol

Answer

Diltiazem

Answer

Quinidine

Question 3

Niacin must be used cautiously in diabetic patients because?

Accepted Answer

It impairs insulin sensitivity

Answer

It causes hypoglycemia

Answer

It increases the metabolism of oral hypoglycemic agents

Answer

It increases skin thickness

Question 4

Which drug class inhibits the rate-limiting step in cholesterol synthesis?

Accepted Answer

Statins

Answer

Probucol

Answer

Cholestyramine

Answer

Gemfibrozil

Question 5

Nitrate causes all of the following EXCEPT:

Accepted Answer

Increase in cardiac work

Answer

Decrease in heart size

Answer

Preload reduction

Answer

Dilatation of cutaneous blood vessels

Question 6

Riociguat is used in the treatment of:

Accepted Answer

Chronic thromboembolic pulmonary hypertension

Answer

Gouty arthritis

Answer

Rheumatoid arthritis

Answer

Obesity

Question 7

A diabetic patient with bilateral renal artery stenosis requires a drug for the treatment of high blood pressure. Which of the following drugs will be most appropriate for this patient?

Accepted Answer

Amlodipine

Answer

Hydrochlorothiazide

Answer

Metoprolol

Answer

Enalapril

Question 8

Propranolol can be used in all of the following conditions except?

Accepted Answer

Variant angina

Answer

Thyrotoxicosis

Answer

Migraine

Answer

Hypertension

Question 9

Which of the following is a potassium channel opener?

Accepted Answer

Nicorandil

Answer

Ranolazine

Answer

Ivabradine

Answer

Nitroprusside

Question 10

Which of the following statements is NOT true regarding the use of beta-blockers in Congestive Heart Failure?

Accepted Answer

Beta-blockers are the drug of choice in acute decompensated heart failure.

Answer

Beta-blockers should be started at a very low dose and slowly titrated upwards.

Answer

Carvedilol is a widely used beta-blocker in CHF.

Answer

Beta-blockers can reduce mortality in CHF patients.

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?